Utah Life Science Summit 2015 5 Nov. 2015 Phil Triolo, PhD RAC President, Phil Triolo and Associates LC.

Slides:



Advertisements
Similar presentations
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Advertisements

Regulatory Pathway for Platform Technologies
Strengthening the Medical Device Clinical Trial Enterprise
Development of Guidance Documents Jennifer Scharpf, M. P. H
510k Submission Overview Myraqa, Inc. August 22, 2012.
1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.
CFSAN’s Peer Review for Risk Assessments Robert L. Buchanan, Sherri Dennis, and Marianne Miliotis.
Medical Device User Fee Reauthorization & FDA Update Roadmap to a Successful 510(K) Submission For Your Medical Device August 22, 2012.
Introduction to Regulation
CADTH Therapeutic Reviews
Special Topics in IND Regulation
Medical Devices Approval Process
CDRH Software Regulation
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Radiological Devices Advisory Committee Meeting November 18, 2009 John A. DeLucia iCAD, Inc.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.
Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
Slide 1 of 20 Rob Packard, President FRM-023 A D1 – Management Review Template Management Review Management.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
Clinical Trial Review and Approval: New Regulations and their implications Siddika Mithani, Ph.D Clinical Trials & Special Access Programme Therapeutic.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
UNCLASSIFIED10/12/ :41 AM Slide 1 Division of Regulated Activities and Compliance.
March 28, 2006 Combination Products: Preparing for the Journey March 28, 2006 Pamela J. Weagraff Principal Consultant.
1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.
FDA’s Draft LDT Framework & Personalized Medicine Update
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
1 Accredited Standards Committee C63 ® - EMC Subcommittee 8 Bob DeLisi Chair
1 Combination Products: Jurisdictional Issues MassMEDIC Presentation March 28, 2006 Janice Hogan, Esq. Partner Hogan & Hartson, LLP
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
MDIC 1 George Serafin Deloitte & Touche LLP MDIC Open Forum Quality System Maturity Model Update.
Regulatory Decision Making D. Kathleen Wright, Reviewer Division of Microbiology Office of In Vitro Diagnostic Device Evaluation & Safety ( OIVD ) Food.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Investigational Devices and Humanitarian Use Devices June 2007.
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
CDRH Update Jeff Shuren Food and Drug Administration Center for Devices and Radiological Health November 5, 2015 Center for Devices and Radiological Health1.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
HUD and Emergent Use Walter Kraft. Device Classification Significant risk – Often involve an invasive procedure for implantation or use – Requires IDE.
Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
AMERICAS | ASIA PACIFIC | EMEA Medical Devices: Concept to Commercialization How to avoid delays in getting your product cleared/approved by FDA Robert.
OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February 26, 2014.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
Fireside Chat Playing By The Rules: Navigating The Regulation Pathway Plamena Entcheva-Dimitrov, PhD, RAC, Founder and Principal Consultant – PREFERRED.
Device Updates in FDASIA MDUFA III RA SAIC – 9 th April 2013 Karen Jaffe, MS, MBA, RAC or
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.
FDA's Two New Draft Guidance on Software and Device
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
MEM Cybersecurity Working Group Update to PCD Technical Committee
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
Guidance for review of studies involving HCT/Ps and IND Basics
Division of Cardiovascular Devices
U.S. FDA Center for Devices and Radiological Health Update
MEM Cybersecurity Working Group Update to PCD Technical Committee
Premarket Notification 510(k) process
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
FDA’s IDE Decisions and Communications
Balancing Pre and Postmarket Requirements Different Scenarios
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
FDA GUI Summary of Contract Manufacturing Arrangement for Drugs: Quality Agreements November This summary was prepared by the Rx-360.
FDA-CDRH in the Next Decade A Vision for Change
HL7 International January Working Group Meeting Health Care Device WG
Linda M. Chatwin, Esq. RAC Business Manager, UL LLC
Opening an IND: Investigator Perspective
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

Utah Life Science Summit Nov Phil Triolo, PhD RAC President, Phil Triolo and Associates LC

Overview One element of the FDA and all regulatory bodies) that is constant is change. This brief presentation will identify some of the major changes in FDA guidance and new initiatives that are relevant to medical device manufacturers. Details can be provided at future sessions, depending on interest/feedback. 2 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

Changes that have already been implemented (but you may be catching up…) UDI (Universal Device Identifier) Requirements e/UniqueDeviceIdentification/ eMDR (electronic Medical Device Reporting) e/PostmarketRequirements/ReportingAdverseEvents/eMDR%E2 %80%93ElectronicMedicalDeviceReporting/ucm htm pMAP (pilot Multipurpose Audit Program) e/PostmarketRequirements/ThirdPartyInspection/ucm htm 3 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

Changes that have already been implemented (but you may be catching up…) Cybersecurity m htm Parallel Review nnouncements/ucm htm MemorandaofUnderstandingMOUs/DomesticMOUs/ucm htm announcement 4 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

On the horizon- Significant Impact (when applicable) Lab Developed Tests (Moj will address these) da-and-cms-form-task-force-on-ldt-quality- requirements/ Patient Engagement Advisory Committees da-announces-first-ever-patient-engagement- advisory-committee/ 5 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Guidance Documents Guidance/GuidanceDocuments/ucm htm Guidance/GuidanceDocuments/ucm htm Global Unique Device Identification Database (GUDID): Data Submission Compliance Date of September 24, Guidance for Industry and Food and Drug Administration Staff Global Unique Device Identification Database (GUDID): Data Submission Compliance Date of September 24, Guidance for Industry and Food and Drug Administration Staff Unique Device Identification: Direct Marking of Devices - Draft Guidance for Industry and Food and Drug Administration Staff Unique Device Identification: Direct Marking of Devices - Draft Guidance for Industry and Food and Drug Administration Staff 6 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Guidance Documents Intent to Exempt Certain Unclassified, Class II, and Class I Reserved Medical Devices from Premarket Notification Requirements - Guidance for Industry and Food and Drug Administration Staff (updated list) Intent to Exempt Certain Unclassified, Class II, and Class I Reserved Medical Devices from Premarket Notification Requirements - Guidance for Industry and Food and Drug Administration Staff Refuse to Accept Policy for 510(k)s - Guidance for Industry and Food and Drug Administration Staff (new checklist) Refuse to Accept Policy for 510(k)s - Guidance for Industry and Food and Drug Administration Staff 7 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Guidance Documents Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions - Guidance for Industry and Food and Drug Administration Staff Expedited Access for Premarket Approval and De Novo Medical Devices Intended for Unmet Medical Need for Life Threatening or Irreversibly Debilitating Diseases or Conditions - Guidance for Industry and Food and Drug Administration Staff Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval - Guidance for Industry and Food and Drug Administration Staff more post-mkt considerations Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval - Guidance for Industry and Food and Drug Administration Staff 8 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Guidance Documents Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling - Guidance for Industry and Food and Drug Administration Staff Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling - Guidance for Industry and Food and Drug Administration Staff Establishing Safety and Compatibility of Passive Implants in the Magnetic Resonance (MR) Environment - Guidance for Industry and Food and Drug Administration Staff Establishing Safety and Compatibility of Passive Implants in the Magnetic Resonance (MR) Environment - Guidance for Industry and Food and Drug Administration Staff Safety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications - Guidance for Industry and Food and Drug Administration Staff Safety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications - Guidance for Industry and Food and Drug Administration Staff 9 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Guidance Documents Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices - Guidance for Industry and Food and Drug Administration Staff Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices - Guidance for Industry and Food and Drug Administration Staff Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems - Guidance for Industry and Food and Drug Administration Staff Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems - Guidance for Industry and Food and Drug Administration Staff 10 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Draft Guidance Documents Guidance/GuidanceDocuments/ucm htm Guidance/GuidanceDocuments/ucm htm Current Good Manufacturing Practice Requirements for Combination Products Current Good Manufacturing Practice Requirements for Combination Products General Considerations for Animal Studies for Medical Devices - Draft Guidance for Industry and Food and Drug Administration Staff General Considerations for Animal Studies for Medical Devices - Draft Guidance for Industry and Food and Drug Administration Staff Draft Guidance for Industry and Food and Drug Administration Staff - Applying Human Factors and Usability Engineering to Optimize Medical Device Design Draft Guidance for Industry and Food and Drug Administration Staff - Applying Human Factors and Usability Engineering to Optimize Medical Device Design 11 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Draft Guidance Documents Homologous Use of Human Cells, Tissue, and Cellular and Tissue-Based Products; Draft guidance for Industry and FDA Staff Homologous Use of Human Cells, Tissue, and Cellular and Tissue-Based Products; Draft guidance for Industry and FDA Staff Assessment of Radiofrequency-Induced Heating in the Magnetic Resonance (MR) Environment for Multi- Configuration Passive Medical Devices - Draft Guidance for Industry and Food and Drug Administration Staff Assessment of Radiofrequency-Induced Heating in the Magnetic Resonance (MR) Environment for Multi- Configuration Passive Medical Devices - Draft Guidance for Industry and Food and Drug Administration Staff Information to Support a Claim of Electromagnetic Compatibility (EMC) of Electrically-Powered Medical Devices - Draft Guidance for Industry and Food and Drug Administration Staff (PDF - 325KB) Information to Support a Claim of Electromagnetic Compatibility (EMC) of Electrically-Powered Medical Devices - Draft Guidance for Industry and Food and Drug Administration Staff (PDF - 325KB) 12 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Draft Guidance Documents Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices - Draft Guidance for Industry and Food and Drug Administration Staff (PDF - 1.1MB) Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices - Draft Guidance for Industry and Food and Drug Administration Staff (PDF - 1.1MB) Adaptive Designs for Medical Device Clinical Studies - Draft Guidance for Industry and Food and Drug Administration Staff Adaptive Designs for Medical Device Clinical Studies - Draft Guidance for Industry and Food and Drug Administration Staff 13 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Draft Guidance Documents Acceptance of Medical Device Clinical Data from Studies Conducted Outside the United States - Draft Guidance for Industry and Food and Drug Administration Staff Acceptance of Medical Device Clinical Data from Studies Conducted Outside the United States - Draft Guidance for Industry and Food and Drug Administration Staff Procedures for Meetings of the Medical Devices Advisory Committee - Draft Guidance for Industry and Food and Drug Administration Staff Procedures for Meetings of the Medical Devices Advisory Committee - Draft Guidance for Industry and Food and Drug Administration Staff Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions - Draft Guidance for Investigational Device Exemption Sponsors, Sponsor-Investigators, and Food and Drug Administration Staff (PDF - 877KB) Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions - Draft Guidance for Investigational Device Exemption Sponsors, Sponsor-Investigators, and Food and Drug Administration Staff (PDF - 877KB) 14 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Draft Guidance Documents Patient Preference Information - Submission, Review in PMAs, HDE Applications, and De Novo Requests, and Inclusion in Device Labeling - Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders Patient Preference Information - Submission, Review in PMAs, HDE Applications, and De Novo Requests, and Inclusion in Device Labeling - Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders Use of International Standard ISO-10993, Biological Evaluation of Medical Devices Part 1: Evaluation and Testing - Draft Guidance for Industry and Food and Drug Administration Staff Use of International Standard ISO-10993, Biological Evaluation of Medical Devices Part 1: Evaluation and Testing - Draft Guidance for Industry and Food and Drug Administration Staff 15 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Draft Guidance Documents General Wellness: Policy for Low Risk Devices - Draft Guidance for Industry and Food and Drug Administration Staff (PDF - 550KB) General Wellness: Policy for Low Risk Devices - Draft Guidance for Industry and Food and Drug Administration Staff (PDF - 550KB) Medical Device Accessories: Defining Accessories and Classification Pathway for New Accessory Types - Draft Guidance for Industry and Food and Drug Administration Staff (PDF - 309KB) Medical Device Accessories: Defining Accessories and Classification Pathway for New Accessory Types - Draft Guidance for Industry and Food and Drug Administration Staff (PDF - 309KB) 16 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

New Draft Guidance Documents Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices - Draft Guidance for Industry and Food and Drug Administration Staff Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices - Draft Guidance for Industry and Food and Drug Administration Staff Draft Guidance for Industry and FDA Staff - Premarket Notification [510(k)] Submissions for Medical Devices that Include Antimicrobial Agents Draft Guidance for Industry and FDA Staff - Premarket Notification [510(k)] Submissions for Medical Devices that Include Antimicrobial Agents Heparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing - Draft Guidance for Industry and Food and Drug Administration Staff Heparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing - Draft Guidance for Industry and Food and Drug Administration Staff 17 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

Looking Ahead- FDA’s 2015 Guidance Document “to do” list Final Guidance: Use of International Standard ISO , "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing“ (Thor Rollins wrote a 3-part article on the draft that is published in MDDI.) 18 FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015

Questions or Comments Feel free to contact me: Phil Triolo, PhD RAC Phil Triolo and Associates LC or FDA Update Phil Triolo Sr. Consultant Phil Triolo and Associates LC BioUtah Life Science Summit 5 Nov. 2015